NASDAQ · MDXG
Healthcare · Biotechnology
$3.90
Up+$0.05 (+1.28%)
Updated Oct 28, 2026, 10:58 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MDXG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 27, 2026
MDXG closed at $3.90 after 21 trading sessions, down 16.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 27, 2026 | $3.86 | $3.90 | $3.79 | $3.90 | 1.92M |
| Oct 26, 2026 | $3.93 | $3.93 | $3.815 | $3.85 | 1.11M |
| Oct 23, 2026 | $3.90 | $3.93 | $3.85 | $3.91 | 1.26M |
| Oct 22, 2026 | $3.70 | $4.025 | $3.67 | $3.93 | 1.58M |
| Oct 21, 2026 | $4.20 | $4.20 | $3.73 | $3.74 | 2.6M |
| Oct 20, 2026 | $4.40 | $4.46 | $4.21 | $4.23 | 1.63M |
| Oct 19, 2026 | $4.44 | $4.47 | $4.26 | $4.38 | 2.69M |
| Oct 16, 2026 | $4.66 | $4.69 | $4.40 | $4.43 | 2.73M |
| Oct 15, 2026 | $4.76 | $4.875 | $4.655 | $4.68 | 1.33M |
| Oct 14, 2026 | $4.65 | $4.74 | $4.64 | $4.70 | 1.64M |
| Oct 13, 2026 | $4.86 | $4.87 | $4.68 | $4.69 | 972.93K |
| Oct 12, 2026 | $4.68 | $4.84 | $4.63 | $4.83 | 625.57K |
| Oct 9, 2026 | $4.58 | $4.695 | $4.58 | $4.67 | 391.12K |
| Oct 8, 2026 | $4.58 | $4.625 | $4.475 | $4.62 | 1.08M |
| Oct 7, 2026 | $4.58 | $4.68 | $4.57 | $4.61 | 821.15K |
| Oct 6, 2026 | $4.59 | $4.65 | $4.48 | $4.62 | 1.05M |
| Oct 5, 2026 | $4.58 | $4.695 | $4.55 | $4.55 | 894.73K |
| Oct 2, 2026 | $4.69 | $4.69 | $4.485 | $4.59 | 1.37M |
| Oct 1, 2026 | $4.65 | $4.68 | $4.57 | $4.64 | 1.19M |
| Sep 30, 2026 | $4.70 | $4.70 | $4.565 | $4.66 | 1.03M |
| Sep 29, 2026 | $4.65 | $4.685 | $4.58 | $4.67 | 901.2K |
The latest Smart Investors Daily articles mentioning MDXG.
Company
Market Activity
Research & News
MDXG research
Company profile and research snapshot.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Craig-Hallum | Buy | — |
| Aug 17, 2026 | Cantor Fitzgerald | Overweight | — |
| Apr 30, 2026 | Citizens | Market Outperform | — |
| Apr 20, 2026 | Citizens | Market Outperform | — |
| Apr 17, 2026 | Craig-Hallum | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 16, 2026
The Federal Trade Commission issued a Second Request on Friday, seeking additional documents and information from both companies for the merger.
Benzinga · Oct 16, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/1376339/000121390026110041/ea0308833-8k425_mimedx.htm
Yahoo · Oct 14, 2026
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following informatio
Yahoo · Sep 23, 2026
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable rul
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDXG.
